Validity of tests for initial diagnosis and its concordance with final diagnosis in patients with suspected benign prostatic hyperplasia;Validez de las pruebas utilizadas en el diagnóstico inicial y su concordancia con el diagnóstico final en pacientes con sospecha de hiperplasia benigna de próstata

Actas Urologicas Espanolas

Volumn 30, Issue 7, 2006, Pages 667-674

  Carballido Rodriguez J ^a   Badia Llach, X ^b   Gimeno Collado, A ^c   Regadera Sejas, L ^d   Dal Re Saavedra R ^d   Guilera Sarda M ^b  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b Health Outcomes Research Europe   (Spain)

^c Hospital General de la Mancha   (Spain)

^d GLAXOSMITHKLINE   (Spain)

Author keywords

Benign prostatic hyperplasia; Diagnosis; Primary health care

Indexed keywords

EID: 33845334529     PISSN: 02104806     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0210-4806(06)73516-1     Document Type: Article

References (23)

1. Chicharro-Molero JA, Burgos-Rodriguez R, Sanchez-Cruz JJ, Rosal-Samaniego JM, Rodero-Carcia P, Rodriguez-Vallejo JM. Prevalence of benign prostatic hyperplasia in Spanish men 40 years old or older. J Urol. 1998;159(3): 878-882.
2. Chute CG, Panser LA, Girman CJ, Oesterling JE, Guess HA, Jacobsen SJ, et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol. 1993;150(1): 85-89.
3. Anderson JB, Roehrborn CG, Schalken JA, Emberton M. The progresión of benign prostatic hyperplasia: examining the evidence and determining the risk. Eur Urol. 2001; 39:390-399.
4. Madersbacher S, Alivizatos G, Nordling J, Rioja C, Emberton M, de la Rosette J. EAU 2004 Guidelines on Assessment, therapy and follow-up of men with Lower Urinary Tract Symptons suggestive of benign prostatic obstruction (BPH Guidelines). Eur Urol. 2004;46:547-554.
5. Chatelain L, Denis L, Foo JK. Evaluation and treatment of lower urinary tract symptoms in older man. In: Recommendations of the International Scientific Committee. Health Publication Ltd. 2001;8:519-534.
6. Barry MJ, Fowler FJ, Jr., O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992;148(5):1549-1557.
7. Badia X, Garcia-Losa M, Dal-Re R, Carballido J, Serra M. Validation of a harmonized Spanish version of the IPSS: evidence of equivalence with the original American scale. International Prostate Symptom Score. Urology 1998;52(4): 614-620.
8. Unda Urzaiz M., Rodriguez Alcantara F, Badia X., Garcia Losa M, Carballido Rodriguez J., Dal-Re Saavedra R. Características sociosanitarias y diagnósticas del paciente prostático en España a finales del siglo XX. Actas Urol Esp 2001;25(3):200-206.
9. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132(3):474-479.
10. Carballido Rodriguez JA, Rodriguez Vallejo JM, Llano Senaris JE. Hiperplasia prostática benigna y medicina basada en la evidencia: su aproximación a la práctica clinica. Med Clin. (Barc) 2000;114 Suppl 2:96-104.
11. Chapple CR. Lower urinary tract symptoms suggestive of benign prostatic obstruction-Triumph: design and implementation. Eur Urol 2001; 39 Suppl 3:31-36.
12. Gomez Acebo A., Rodriguez Vallejo JM., Rodriguez Mora V, Garcia Alcazar I. Calidad de vida y sintomatología en la hiperplasia prostática benigna en la población activa española. Med Clin (Barc) 2000;114 Suppl 3:81-89.
13. Hunter DJ, Berra-Unamuno A, Martin-Gordo A. Prevalence of urinary symptoms and other urological conditions in Spanish men 50 years old or older. J Urol. 1996;155(6): 1965-1970.
14. Sagnier PP, MacFarlane G, Richard F, Botto H, Teillac P, Boyle P. Results of an epidemiological survey using a modified American Urological Association symptom index for benign prostatic hyperplasia in France. J Urol. 1994;151(5): 1266-1270.
15. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991;338:469-471.
16. Scarpa RM. Lower urinary tract symptoms: what are the implications for the patients? Eur Urol.. 2001;40 Suppl 4: 12-20.
17. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33(1):159-174.
18. Roehrborn CG, The potential of serum prostate-specific antigen as a predictor of clinical response in patients with lower urinary tract symptoms and benign prostatic hyperplasia. BJU Int. 2004;93 Suppl 1:21-26.
19. Plante M, Corcos J, Gregoire I, Belanger MF, Brock G, Rossingol M. The international prostate symptom score: physician versus self-administration in the quantification of symptomatology. Urology 1996;47(3):326-328.
20. Carroll P, Coley C, McLeod D, Schellhammer P, Sweat G, Wasson J et al. Prostate-specific antigen best practice policy-part I: early detection and diagnosis of prostate cancer. Urology 2001;57(2):217-224.
21. Roehrborn CG, Boyle P,Gould AL, Waldstreiher J. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 1999;53(3):581-589.
22. McConnell JD, Roehborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, et al. The long term effect of doxazosin, finasteride and combination therapy on the clinical progression of benign prostatic hyperplasia. N Eng J Med. 2003;349:2387-2398.
23. Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J. The Prostate Specific Antigen era in the United States is over for prostate cancer: What happened in the Last 20 years? J Urol. 2004;172(4 Pt1):1297-1301.